IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER

Abstract

Abstract. Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.

Keywords

• Bestim
• immunity
• Т–helpers
• Helicobacter pylori
• gastric ulcer disease